Possible Genetic Treatment Pathways for Turner’s Syndrome (TS)

Authors

• Afua Dwamena Frimpong, University of LynchburgFollow

Specialty

Primary care, genetics

Advisor

Christopher Cannell DMSc, MPLC, MPAS, PA-C, DFAAPA

Abstract

Introduction: Turner’s Syndrome (TS) is a rare genetic condition affecting 1 in every 2,000-2,500 girls and women globally.1 TS is caused by the partial presence or silence of an X Chromosome [haploinsufficiency]. TS has no treatment, and is, instead managed by lifelong hormone replacement and supportive therapies. This study recommends a medical research breakthrough involving the X Chromosome Reactivation (XCR).

Hypothesis: Using XCR, the targeted suppression of XIST-gene alongside epigenetic regulation will induce partial and sustained reactivation of the silent X chromosome, resulting in improved or restored functionally among patients.

Discussion/Methods: TS causes kidney problems, vision problems, skeletal abnormalities, hearing deficiencies, ovarian problems, cognitive issues, congenital heart defects, and developmental challenges in women.2,4 Existing interventions include lifelong dependence on pharmacological [hormone therapy] and non-pharmacological therapies. XCR can help treat the condition if aggressively pursued.

Qualitative research grounded on systematic reviews facilitated data collection from 18 peer-reviewed journals. Due to the inclusion/exclusion criteria, only 4 were relevant to the context, given issues of recency, data quality, relevance, and validity. A synthesis of the selected journals involved identification of recurrent biological themes in these articles, TS etiology, haploinsufficiency, and the inactivation/reactivation of X chromosome, the role played by XIST in silencing, and possible XCR mechanisms.

Results: 

• The TS-related genes are closely associated with X-linked gene haploinsufficiency, indicating that XCR-mediated restoration could improve physiological function by 63%.3 

• These genes avoid X-chromosome inactivation and regulate cell proliferation, ovarian development, cardiac development, metabolism, and brain cognitive functions. Enhanced expression of the related gene will reduce TS manifestation.3 

• XCR targets the core pathophysiology of TS by activating some genes on the inactivated X chromosome.1,3

• XCR ensures 5-15% of the XIST gene [keeps the X chromosome inactivated] are repressed, enabling the reactivation of X chromosome genes.3,4

• There’s a 90% confidence level that XCR treatment will resolve infertility, cognitive, visual, and hearing deficiencies, birth defects, hypertension, osteoporosis, and mental health problems.1,2

Conclusion: TS is caused by an X-linked gene haploinsufficiency, although reactivation of the silent X chromosome is highly plausible with a likely improvement of physiological function by 63% and the XCR trial success rate of 90%.

Recommended Citation

Frimpong AD. Possible Genetic Treatment Pathways for Turner’s Syndrome (TS). University of Lynchburg Doctoral Project Assignment Repository. 2026; 8(2).